Work Productivity in Hyperventilation Syndrome (WHY)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Lille, France
- Hôpital Calmette,CHU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Holders of employment contracts for at least 8 days
- Diagnosis of hyperventilation syndrome confirmed by:
Compatible symptoms and at least two symptoms reproduced by the hyperventilation challenge test: Nijmegen's score> 23 ; Demonstration of alveolar hyperventilation ( Either on rest blood and / or at rest (PaCO2 at rest <36 mmHg and D (A-a) O2 normal; Either during the HV test (increased recovery time of the basic PETCO2 after voluntary hyperventilation (greater than 5 minutes)
Exclusion Criteria:
- Existence of another chronic pulmonary disease (asthma, bronchial dilation, COPD, diffuse interstitial pneumonia, neuromuscular pathology ...) or cardiac (rhythm disorder, ischemic heart disease ...) which can participate in dyspnea
- Psychiatric illness / psychotropic treatment
- Pregnancy
- Patient already included in a clinical research protocol involving new therapeutics may not be included in this protocol
- Specific physiotherapy or previous training
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Hyperventilation syndrome
|
Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association between the WPAI score and the Nijmegen score
Time Frame: At the time of diagnosis (Baseline)
|
At the time of diagnosis (Baseline)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association between the WPAI score and dyspnea scales
Time Frame: At the time of diagnosis (Baseline)
|
At the time of diagnosis (Baseline)
|
|
Association between the WPAI score and quality of life scores
Time Frame: At the time of diagnosis (Baseline)
|
At the time of diagnosis (Baseline)
|
|
Association between the WPAI score and PaCO2
Time Frame: At the time of diagnosis (Baseline)
|
At the time of diagnosis (Baseline)
|
|
Association between the WPAI score and the Cognitive Failure Questionnaire score
Time Frame: At the time of diagnosis (Baseline)
|
At the time of diagnosis (Baseline)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Cécile Chenivesse, MD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2016_68
- 2017-A01542-51 (OTHER: ID-RCB number, ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperventilation Syndrome
-
NCT05100290Completed
-
NCT03159429Terminated
-
NCT05189158CompletedHypoxia | Hypercapnia | Hyperventilation Syndrome
-
NCT04668638Completed
-
NCT03614806CompletedHyperventilation | Hypocapnia | Hyperventilation Syndrome | Alkalosis, Respiratory
-
NCT03043469UnknownBreathlessness | Hyperventilation Syndrome | Respiration Disorder | Breath Shortness
-
NCT01862289CompletedSevere Persistent Asthma | Hyperventilation Syndrome | Difficult Asthma
-
NCT04074798RecruitingLow Back Pain, Recurrent | Hyperventilation Syndrome
-
NCT05224830CompletedCOVID-19 | Hyperventilation Syndrome
Clinical Trials on questionnaire
-
NCT03840109CompletedAnxiety | Psychological Stress
-
NCT01260792CompletedGeneral Population | TDAH | Children Aged 5 to 18 Years
-
NCT04363281Completed
-
NCT00713297UnknownComputerized Physician Order Entry
-
NCT02576483RecruitingAstigmatism | Nearsightedness | Farsightedness
-
NCT06618898CompletedOrofacial Pain | Sleep Problems
-
NCT04498507CompletedCritical Illness | Covid19 | Psychological Stress | Family
-
NCT05099627Not yet recruitingCervical Myelopathy
-
NCT07482982CompletedFirearm Injury | Firearm Safety | Firearm Ownership